Epilepsy diagnosis is an imperfect science. Approximately 30% of patients are misdiagnosed after their first visit.

Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and relutrigine set for 2025. See more on PRAX here.

The mislabeling poses a significant health risk, as patients receiving the drug could inadvertently be administered double ...

"Generalist medical practitioners receive limited training and exposure to epilepsy. Most are trained to recognize generalized and convulsive seizures: obvious signs of the condition. However ...

Over 40% of the most dangerous generalized tonic-clonic seizures are ... Orrin Devinsky, director of the Comprehensive Epilepsy Center at NYU commented: "The FDA approval of the Embrace device ...

and generalized epilepsy with vormatrigine, and the initiation of our EMERALD registrational study of relutrigine in developmental epilepsies and encephalopathies (DEEs) by mid-year 2025. We maintain ...

It can be scary in the moment if your dog has a seizure - especially if they've never had one before. Here's are the steps to ...

The FDA expanded the indication of eculizumab (Soliris) to include pediatric patients ages 6 and older with generalized ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.

FDA submission planned in second half of 2025 Announced that data demonstrating best in class efficacy results from the ongoing Post-approval Study of the RNS System in adults with drug-resistant ...